Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma)

Giornale Italiano di Dermatologia e Venereologia

Volumn 143, Issue 6, 2008, Pages 375-383

  Wong, H K ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b Dermatology Research   (United States)

Author keywords

Cutaneous Monitoring; Immunologic Gene expression Cytokines; Mycosis fungoides Lymphoma; T cell

Indexed keywords

CYTOKINE;

CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS FUNGOIDES; PHENOTYPE; REVIEW; SEZARY SYNDROME; TUMOR IMMUNITY;

EID: 59749099656     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22.
2. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-88.
3. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet 2008;371:945-57.
4. Alibert J. Description des maladies de la peau observées a l'Hôpital Saint-Louis, et exposition des meilleures méthodes suivies pour leur traitement. Paris: Barrois l'aine; 1806.
5. Medenica M, Lorincz AL. Pagetoid reticulosis (Woringer-Kolopp disease). Histopathologic and ultrastructural observations. Arch Dermatol 1978;114:262-8.
6. Kim YH, Hoppe RT. Mycosis fungoides and the Sézary syndrome. Semin Oncol 1999;26:276-89.
7. Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol 2006;(33 Suppl l):27-42.
8. Willemze R, van Vloten WA, Hermans J, Damsteeg MJ, Meijer CJ. Diagnostic criteria in Sézary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. J Invest Dermatol 1983;81:392-7.
9. Burg G, Kempf W, Cozzio A, Feit J, Willemze R, E SJ, Dummer R et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 2005;32:647-74.
10. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005;115:798-812.
11. Burg G, Dummer R, Haeffner A, Kempf W, Kadin M. From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors. Arch Dermatol 2001;137:949-52.
12. Morales Suarez-Varela MM, Llopis Gonzalez A, Marquina Vila A, Bell J. Mycosis fungoides: review of epidemiological observations. Dermatology 2000;201:21-8.
13. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Ixmg-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857-66.
14. Morales MM, Putcha V, Evans HS, Olsen J, Llopis A, Moller H. Survival of mycosis fungoides in patients in the Southeast of England. Dermatology 2005;211:325-9.
15. Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005;153: 118-24.
16. van Doom R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10.
17. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053-63.
18. Tracey L, Villuendas R, Dotor AM, Spiteri I, Ortiz P, Garcia JF et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 2003;102:1042-50.
19. Jones D, Duvic M. The current state and future of clonality studies in mycosis fungoides. J Invest Dermatol 2003;121:ix-x.
20. Vonderheid EC, Tan E, Sobel EL, Schwab E, Micaily B, Jegasothy BV. Clinical implications of immunologic phenotyping in cutaneous T cell lymphoma. J Am Acad Dermatol 1987; 17:40-52.
21. Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, McCor-mack C. Long term outcomes of patients with advanced-stage cutaneous T cell lymphoma and large cell transformation. Blood 2008;112:3082-7
22. Nickoloff BJ. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol 1988;10:469-77.
23. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005;105:1640-7.
24. Gazdar AF, Carney DN, Russell EK, Schechter GP, Bunn PA, Jr. In vitro growth of cutaneous T-cell lymphomas. Cancer treatment reports 1979;63:587-90.
25. McCusker ME, Garifallou M, Bogen SA. Sézary lineage cells can be induced to proliferate via CD28-mediated costimulation. J Immunol 1997;158:4984-91.
26. Sterry W, Mielke V. CD4+ cutaneous T-cell lymphomas show the phenotype of helper/inducer T cells (CD45RA-, CDw29+). J Invest Dermatol 1989;93:413-6.
27. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106.
28. Yamaguchi T, Ohshima K, Tsuchiya T, Suehuji H, Karube K, Nakayama J et al. The comparison of expression of cutaneous lymphocyte- associated antigen (CLA), and Thl-and Th2-associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lym-phoma. Eur J Dermatol 2003;13:553-9.
29. Wood GS, Hong SR, Sasaki DT, Abel EA, Hoppe RT, Warnke RA et al. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values. J Am Acad Dermatol 1990;22: 602-7.
30. Laetsch B, Haffner AC, Dobbeling U, Seifert B, Ludwig E, Burg G, Dummer R. CD4 + /CD7- T cell frequency and polymerase chain reaction-based clonality assay correlate with stage in cutaneous T cell lymphomas. J Invest Dermatol 2000;114:107-11.
31. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001;115:885-92.
32. Nikolova M, Echchakir H, Wechsler J, Boumsell L, Bensussan A, Bagot M. Isolation of a CD8alphaalpha+ CD4- tumour T-cell clone with cytotoxic activity from a CD4+ CD8- cutaneous T-cell lymphoma. Br J Dermatol 2003;148:24-9.
33. Mohr B, Illmer T, Oelschlagel U, Nowak R, Holig K, Paaz U et al. Complex cytogenetic and immunophenotypic aberrations in a patient with Sezary syndrome. Cancer Genet Cytogenet 1996;90:33-6.
34. Vowels BR, Lessin SR, Cassin M, Jaworsky C, Benoit B, Wolfe JT et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994;103:669-73.
35. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 1996;88:1383-9.
36. Papadavid E, Economidou J, Psarra A, Kapsimali V, Mantzana V, Antoniou C et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 2003;148:709-18.
37. Wood GS, Edinger A, Hoppe RT, Warnke RA. Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T-lymphocyte phenotype. J Cutan Pathol 1994;21:151-6.
38. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor- infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995;32:448-53.
39. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111:645-9.
40. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52.
41. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
42. Chong BF, Wilson AJ, Gibson HM, Hafner MS, Luo Y, Hedgcock CJ et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 2008; 14: 646-53.
43. Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by
44. T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 1999;6:79-84.
45. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007;13:242-4.
46. Bowcock AM, Krueger JG. Getting under the skin: the immuno-genetics of psoriasis. Nat Rev Immunol 2005;5:699-711.
47. Ehlers S, Smith KA. Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory. J Exp Med 1991; 173: 25-36.
48. Krishnan S, Warke VG, Nambiar MP, Wong HK, Tsokos GC, Farber DL. Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3zeta expression. Blood 2001;97:3851-9.
49. Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock CJ, Berger CL et al. Increased expression of ctla-4 in malignant T-cells from patients with mycosis fungoides - cutaneous T cell lymphoma. J Invest Dermatol 2006;126:212-9.
50. Capriotti E, Vonderheid EC, Thoburn CJ, Wasik MA, Bahler DW, Hess AD. Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 2008;49:1190-201.
51. Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006;126:2217-23.
52. Posner LE, Fossieck BE, Jr., Eddy JL, Bunn PA, Jr. Septicemic complications of the cutaneous T-cell lymphomas. The American journal of medicine 1981;71:210-6.
53. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sézary syndrome. Jama 1992;267:1354-8.
54. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
55. Burnet M. Cancer; a biological approach. I. The processes of control. British medical journal 1957;1:779-86.
56. Thomas L. Reactions to homologous tissue antigens in relation to hypersensitivity [Discussion]. In: Lawrence H, editor. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper; 1959. p. 529-32.
57. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974;183:534-6.
58. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
59. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
60. Caligiuri MA. Human natural killer cells. Blood 2008;112:461-9.
61. Oldham RK. Natural killer cells: artifact to reality: an odyssey in biology. Cancer Metastasis Rev 1983;2:323-36.
62. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
63. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-61.
64. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative JEN gamma receptors. Immunity 1994;1:447-56.
65. Dummer R, Geertsen R, Ludwig E, Niederer E, Burg G. Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1). Leuk Lymphoma 1998;28:515-22.
66. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001;7:2682-92.
67. Kaye FJ, Bunn PA, Jr., Steinberg SM, Stocker JL, Ihde DC, Fischmann AB et al A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
68. Yanagi T, Shimizu T, Ujiie H, Ito M, Abe R, Tsuji-Abe Y et al. Peginterferon alfa-2b for mycosis fungoides. Arch Dermatol 2006; 142: 649-51.
69. Vonderheid EC, Thompson R, Smiles KA, Lattanand A. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Arch Dermatol 1987;123:757-63.
70. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16:311 -21.
71. Thestrup-Pedersen K, Hammer R, Kaltoft K, Sogaard H, Zachariae H. Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate. Br J Dermatol 1988;118: 811-8.